Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Regeneron Pharmaceuticals enters into asset purchase agreement to acquire 23andMe for $256 million: Tarrytown, New York Wednesday, May 21, 2025, 13:00 Hrs [IST] Regeneron Pharmace ...

Patients with asthma who did not persist with biologic treatment had more exacerbations and used more oral corticosteroids, ...

Regeneron Pharmaceuticals has said it will preserve the privacy of 23andMe's genetic data after it acquires the DNA testing ...

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy ...

In March, 23andMe said that it was looking to sell “substantially all of its assets” through a court-approved reorganization plan.

Genetic testing company 23andMe is being acquired, shortly after it declared bankruptcy months ago.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary, Lemonaid ...

Regeneron Pharmaceuticals announced it won the bankruptcy auction for key assets of 23andMe, according to Benzinga. The $256 ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

The last time we talked about 23andMe’s bankruptcy sale, we suggested you might want to delete your genetic data from the ...

On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...